CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Retained Earnings	FlexBiosys, Inc.	FlexBiosys, Inc. Common Stock	FlexBiosys, Inc. Additional Paid-In Capital
Translation adjustment	$ (8,972)			$ (8,972)
Balance at Dec. 31, 2022	1,910,700	$ 556	$ 1,547,266	(34,394)	$ 397,272
Beginning Balance (in shares) at Dec. 31, 2022		55,557,698
Net Income (Loss)	52,046				52,046
Conversion of debt	(13)	$ 0	(13)
Conversion of debt (in shares)		8
Exercise of stock options and vesting of stock units	356	$ 3	353
Exercise of stock options and vesting of stock units (in shares)		212,589
Tax withholding on vesting of restricted stock units	(12,178)	$ (1)	(12,177)
Tax withholding on vesting of restricted stock units (in shares)		(69,625)
Issuance of common stock pursuant to the acquisition						$ 5,465	$ 0	$ 5,465
Issuance of common stock pursuant to the acquisition, (in shares)							31,415
Issuance of common stock pursuant to contingent consideration earnout payment	7,229	$ 0	7,229
Issuance of common stock pursuant to contingent consideration earnout payments		42,621
Stock-based compensation expense	19,110		19,110
Balance at Sep. 30, 2023	1,973,743	$ 558	1,567,233	(43,366)	449,318
Ending Balance (in shares) at Sep. 30, 2023		55,774,706
Balance at Jun. 30, 2023	1,956,859	$ 557	1,561,393	(37,486)	432,395
Beginning Balance (in shares) at Jun. 30, 2023		55,744,896
Net Income (Loss)	16,923				16,923
Conversion of debt	(10)		(10)
Conversion of debt (in shares)		2
Exercise of stock options and vesting of stock units	294	$ 1	293
Exercise of stock options and vesting of stock units (in shares)		36,195
Tax withholding on vesting of restricted stock units	(1,038)	$ 0	(1,038)
Tax withholding on vesting of restricted stock units (in shares)		(6,387)
Issuance of common stock pursuant to the acquisition						$ 222		$ 222
Stock-based compensation expense	6,373		6,373
Balance at Sep. 30, 2023	1,973,743	$ 558	1,567,233	(43,366)	449,318
Ending Balance (in shares) at Sep. 30, 2023		55,774,706
Translation adjustment	(5,880)			(5,880)
Balance at Dec. 31, 2023	1,964,845	$ 558	1,569,227	(37,808)	432,868
Beginning Balance (in shares) at Dec. 31, 2023		55,766,078
Net Income (Loss)	8,355				8,355
Conversion of debt	(114)	$ 1	(115)
Conversion of debt (in shares)		100,944
Exercise of stock options and vesting of stock units	2,366	$ 2	2,364
Exercise of stock options and vesting of stock units (in shares)		179,335
Tax withholding on vesting of restricted stock units	(9,404)	$ (1)	(9,403)
Tax withholding on vesting of restricted stock units (in shares)		(51,040)
Issuance of common stock pursuant to contingent consideration earnout payment	5,742	$ 0	5,742
Issuance of common stock pursuant to contingent consideration earnout payments		31,408
Stock-based compensation expense	41,711		41,711
Balance at Sep. 30, 2024	2,016,686	$ 560	1,609,526	(34,623)	441,223
Ending Balance (in shares) at Sep. 30, 2024		56,026,725
Translation adjustment	9,822			9,822
Balance at Jun. 30, 2024	1,984,438	$ 559	1,586,447	(44,445)	441,877
Beginning Balance (in shares) at Jun. 30, 2024		55,902,860
Net Income (Loss)	(654)				(654)
Conversion of debt	(7)	$ 1	(8)
Conversion of debt (in shares)		100,942
Exercise of stock options and vesting of stock units	577	$ 0	577
Exercise of stock options and vesting of stock units (in shares)		26,854
Tax withholding on vesting of restricted stock units	(545)	$ 0	(545)
Tax withholding on vesting of restricted stock units (in shares)		(3,931)
Stock-based compensation expense	23,055		23,055
Balance at Sep. 30, 2024	2,016,686	$ 560	$ 1,609,526	(34,623)	$ 441,223
Ending Balance (in shares) at Sep. 30, 2024		56,026,725
Translation adjustment	$ 3,185			$ 3,185